Search Results
Your search for Margaret O matches 23 pages
Showing 1 - 23NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
Marcus O. Butler, MD, on Uveal Melanoma: Tebentafusp and Evidence of Tumor Response
Marcus O. Butler, MD, of Toronto’s Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. Tebentafusp is a first-in-class novel bispecific protein, the first therapy to show superior overall...
RELATIVITY-047: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
In the recently published results of the RELATIVITY-047 trial,1 summarized in this issue of The ASCO Post, the addition of relatlimab to nivolumab monotherapy was associated with improved progression-free survival compared with nivolumab alone in patients with previously untreated advanced,...
ASCO Presidents Through the Years: Past, Present, and Future
2020–2021: Lori J. Pierce, MD, FASTRO 2019–2020: Howard “Skip” Burris, III, MD, FACP 2018–2019: Monica M. Bertagnolli, MD 2017–2018: Bruce E. Johnson, MD 2016–2017: Daniel F. Hayes, MD 2015–2016: Julie Vose, MD, MBA 2014–2015: Peter P. Yu, MD 2013–2014: Clifford A. Hudis, MD 2012–2013: Sandra M....
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards and Tribute Award. The recipients of these awards have worked to transform cancer care around the world. Don’t miss the opportunity...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards and Tribute Award. The recipients of these awards have worked to transform cancer care around the world. Don’t miss the opportunity...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...
ASCO Through the Years: Past Presidents
Over the years many great oncology leaders have served at the helm as ASCO President. We recognize these individuals here, and extend our gratitude for their service and efforts to champion high-quality cancer care. 2018-2019: Monica M. Bertagnolli, MD 2017-2018: Bruce E. Johnson, MD 2016-2017:...
Tackling the High Cost of Cancer Care
AT THE 2017 ASCO ANNUAL MEETING, the leaders of the newly formed Value in Cancer Care Consortium (vi3c; vi3c.org) met to discuss the group’s plan to study how to improve the affordability of cancer drugs and make them more accessible to patients. The goal of the Value in Cancer Care Consortium is...
ASCO Presidents Through the Years
2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...
Pembrolizumab Active in Mucosal Melanoma in KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO).1 Mucosal melanoma has often been excluded from...
Conquer Cancer Foundation Honors 65 Young Oncology Professionals With Merit Awards
The Conquer Cancer Foundation of ASCO (CCF) is pleased to announce the recipients of its 2017 CCF Merit Awards in Gastrointestinal Cancers, Cancer Survivorship, Genitourinary Cancers, Immuno-Oncology, and Quality Care. The following 65 young researchers, recognized for the scientific merit of their ...
AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans
“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...
Lawrence O. Gostin, JD, LLD, Appointed to National Cancer Advisory Board
President Barack Obama has tapped Lawrence O. Gostin, JD, LLD, Georgetown University Professor and Faculty Director of the O’Neill Institute for National and Global Health Law at Georgetown Law, to serve as a member of the National Cancer Advisory Board (NCAB). He will serve a 6-year term. The 18 ...
New Staging System for Human Papillomavirus–Related Oropharyngeal Cancer
As reported in The Lancet Oncology by O’Sullivan et al, a new staging system for human papillomavirus–related oropharyngeal cancer has been developed based on findings from the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S) study. Study Details The...
Bevacizumab in Glioblastoma: Another Perspective
Given the results of the AVAglio trial, we feel that a more balanced discussion about the role of bevacizumab (Avastin) in patients with newly diagnosed glioblastoma is in order. The accompanying article in The ASCO Post suggests that bevacizumab has no benefit in newly diagnosed glioblastoma; data ...
Two Trials Explore the Evolving Role of Bevacizumab in Ovarian Cancer
The optimal use of bevacizumab (Avastin) in ovarian cancer appears to be in high-risk subgroups and in patients with platinum-resistant ovarian cancer, according to results of two phase III trials presented at the 2013 European Cancer Congress (ECC) in Amsterdam. AURELIA investigated the safety and ...
American Association for Cancer Research Inaugurates 2014 Class of Fellows
The American Association for Cancer Research (AACR) inducted the 2014 class of elected Fellows of the AACR Academy at the Association’s Annual Meeting, held recently in San Diego. The AACR Academy is an entity within the AACR that recognizes those individuals who have made exceptional contributions ...
ASCO Through the Years: Past Presidents
This year ASCO celebrates it's 50th Anniversary. Here is a list of past ASCO Presidents over these 50 years: 2014-2015: Peter P. Yu, MD 2013-2014: Clifford A. Hudis, MD 2012-2013: Sandra M. Swain, MD, FACP 2011-2012: Michael P. Link, MD 2010-2011: George W. Sledge, Jr, MD 2009-2010: Douglas W....
Institute of Medicine Elects 70 New Members, 10 Foreign Associates
The Institute of Medicine (IOM) has announced the names of 70 new members and 10 foreign associates during its 44th Annual Meeting held in October. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Breast Health Global Initiative Tackles Third-World Health Care
Benjamin O. Anderson, MD, is the Director of the Breast Health Global Initiative (BHGI) and surgical oncologist and Director of the Breast Health Clinic at the University of Washington in Seattle. The ASCO Post recently spoke with Dr. Anderson about the conceptual framework of the...
HPV-Positive Head and Neck Cancer: When Can Chemotherapy Be Omitted?
Are there patients with locally advanced squamous cell carcinoma of the head and neck associated with human papillomavirus (HPV) for whom chemotherapy can be omitted? Experts debated this question at the 2015 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia,...
Improved TNM Prediction of Survival in HPV‑Related Oropharyngeal Carcinoma
In a study reported in the Journal of Clinical Oncology, Huang et al showed that recursive portioning analysis (RPA) could be used to provide TNM stage grouping with improved prediction of survival in patients with human papillomavirus (HPV)-related nonmetastatic oropharyngeal carcinoma. ...
